Literature DB >> 12189164

A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype.

Tim Cundy1, Madhuri Hegde, Dorit Naot, Belinda Chong, Alan King, Robyn Wallace, John Mulley, Donald R Love, Joerg Seidel, Matthew Fawkner, Tatjana Banovic, Karen E Callon, Andrew B Grey, Ian R Reid, Catherine A Middleton-Hardie, Jillian Cornish.   

Abstract

Idiopathic hyperphosphatasia is an autosomal recessive bone disease characterized by deformities of long bones, kyphosis and acetabular protrusion, increasing in severity as affected children pass through adolescence. Biochemical and histological evidence indicate that there is extremely rapid bone turnover, with indices of both bone resorption and formation greatly increased. A genome-wide search, in a family with three children affected by idiopathic hyperphosphatasia, suggested linkage to a locus on the long arm of chromosome 8 (8q24). The gene TNFRSF11B encoding osteoprotegerin (OPG), which lies within this locus, was an obvious candidate, given the critical role of OPG in regulating osteoclast development. All three affected siblings were homozygous for a 3 bp inframe deletion in exon 3 of the TNFRSF11B gene, resulting in the loss of an aspartate residue. Their parents (who were first cousins) were heterozygous for the mutation. Recombinant wild-type and mutant OPG cDNAs were expressed in human epithelial kidney cells, and secreted OPG was collected from the conditioned medium. In vitro measurements of bone resorption showed that wild-type OPG suppressed bone resorption, whereas the mutant form did not, confirming this to be an inactivating mutation. This description of abnormal OPG function in humans expands the spectrum of genetic bone diseases arising from perturbations of the OPG/RANK-L/RANK system that regulates osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12189164     DOI: 10.1093/hmg/11.18.2119

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  45 in total

Review 1.  New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

Authors:  J C Crockett; D J Mellis; D I Scott; M H Helfrich
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

2.  Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Ioannis Litsas; Zoe Efstathiadou; Marina Kita; Georgios Arsos; Efstratios Moralidis; Athanasios Papatheodorou; Evangelos Terpos
Journal:  J Bone Miner Metab       Date:  2010-06-09       Impact factor: 2.626

Review 3.  Genetic disorders of the skeleton: a developmental approach.

Authors:  Uwe Kornak; Stefan Mundlos
Journal:  Am J Hum Genet       Date:  2003-07-31       Impact factor: 11.025

4.  RANK ligand and the regulation of skeletal remodeling.

Authors:  Norman H Bell
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

5.  Deletion of 8q24 in an adult with mild dysmorphic features, developmental delay, and ketotic hypoglycemia.

Authors:  Benjamin D Solomon; Eileen Lange; Jay Shubrook; F John Service; Gail Herman; Rajaram J Karne; Phillip Gorden; Maximilian Muenke; Constantine A Stratakis
Journal:  Am J Med Genet A       Date:  2010-06       Impact factor: 2.802

6.  Posttranslational modifications in proteins: resources, tools and prediction methods.

Authors:  Shahin Ramazi; Javad Zahiri
Journal:  Database (Oxford)       Date:  2021-04-07       Impact factor: 3.451

7.  Juvenile Paget's disease with heterozygous duplication within TNFRSF11A encoding RANK.

Authors:  Michael P Whyte; Cristina Tau; William H McAlister; Xiafang Zhang; Deborah V Novack; Virginia Preliasco; Eduardo Santini-Araujo; Steven Mumm
Journal:  Bone       Date:  2014-07-23       Impact factor: 4.398

8.  Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation.

Authors:  Forough Saki; Zohreh Karamizadeh; Shiva Nasirabadi; Steven Mumm; William H McAlister; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

9.  Expression of osteoprotegerin, RNAK and RANKL genes in femoral head avascular necrosis and related signaling pathway.

Authors:  Qingtang Miao; Sibin Hao; Hongmei Li; Fang Sun; Xueling Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  RANK, RANKL and osteoprotegerin in bone biology and disease.

Authors:  H L Wright; H S McCarthy; J Middleton; M J Marshall
Journal:  Curr Rev Musculoskelet Med       Date:  2009-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.